All In Biotech

Drug Trial Radar · NCT07211776

A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye Disease

A Multicenter, Double-blinded, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ZL-1109 in Chinese Participants With Thyroid Eye Disease (TED)

Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 108 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

108

Actual

Start

Dec 5, 2025

Primary completion

Mar 14, 2027

Study completion Jan 29, 2028

Sponsor

Lead sponsor
Zai Lab (Shanghai) Co., Ltd.Industry
Sponsor type
Industry
First posted
Oct 8, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Multicenter, Double-blinded, Randomized, Placebo-controlled Phase 3 Study of ZL-1109 in Chinese Participants with Thyroid Eye Disease (TED)

Conditions

  • Thyroid Eye Disease (TED)

Interventions

  • ZL-1109 (VRDN-003)Drug

    ZL-1109 subcutaneous injection

  • PlaceboDrug

    Matching placebo subcutaneous injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proptosis Responder Rate in the study eyeTime frame: At Week 24

Locations

26 sites in 1 country. Site status is shown where the registry gives one.

  • Site01006

    Beijing, China

  • Site01009

    Beijing, China

  • Site01010

    Beijing, China

  • Site01029

    Bengbu, China

  • Site01020

    Changsha, China

  • Site01022

    Chengdu, China

  • Site01031

    Chongqing, China

  • Site01011

    Dalian, China

  • Site01008

    Foshan, China

  • Site01004

    Fuzhou, China

  • Site01007

    Guangzhou, China

  • Site01027

    Guiyang, China

  • Site01018

    Hangzhou, China

  • Site01002

    Hefei, China

  • Site01024

    Jinan, China

  • Site01005

    Luoyang, China

  • Site01017

    Nanchang, China

  • Site01001

    Shanghai, China

  • Site01012

    Shenyang, China

  • Site01023

    Taiyuan, China

  • Site01013

    Tianjin, China

  • Site01016

    Wuxi, China

  • Site01028

    Xi'an, China

  • Site01026

    Yangzhou, China

  • Site01019

    Zhengzhou, China

  • Site01030

    Zhengzhou, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.